|
|
|
FDA Approves First IV Treatment for Postmenopausal Osteoporosis -- Boniva(R) Injection
The U.S. Food and Drug Administration (FDA) has approved Boniva® (ibandronate sodium) Injection, the first intravenous (IV) medication for the treatment of postmenopausal osteoporosis, Roche a
From Market Wire,
1/6/06
| |
|
|
FDA Approves First IV Treatment for Postmenopausal Osteoporosis - Boniva® Injection
New Quarterly Medicine is Unique Alternative For Treatment of Osteoporosis NUTLEY, N.J., and RESEARCH TRIANGLE PARK, N.C., Jan. 6 /PRNewswire/ -- ...
From PR Newswire,
1/6/06
| |
|
|
Software supports service-oriented architecture
Based on Java 2 Enterprise Edition, SSA Open Architecture v5.1 provides open standards-based technology platform. It allows customers to achieve software ...
From Product News Network,
10/4/05
| |
|
|
SSA Global Acquires Boniva Software, Inc.; Addition of talent management suite strengthens SSA HCM capabilities
CHICAGO -- SSA Global Technologies, Inc.(TM) (NASDAQ:SSAG), a global provider of extended enterprise solutions and services, today announced the acquisition ...
From Business Wire,
8/8/05
| |
|
|
Pharmaceutical: top 50 packages
PHARMACEUTICAL
From Food & Drug Packaging,
7/1/05
| |
|
|
Boniva ``ibandronate sodium'' Fragile Cities Index Identifies America's Most Fragile Cities; First Ranking of Cities at Risk for Osteoporosis
Fragile is not a word you associate with cities like New York or Pittsburgh. But when it comes to brittle bone disease or osteoporosis, the Boniva Fragile ...
From Business Wire,
5/12/05
| |
|
|
Compliance issues seen with bisphosphonate regimens
WASHINGTON -- Postmenopausal women with osteoporosis can reduce their risk for fractures by 26% if they will adhere to their bisphosphonate regimens, ...
From OB/GYN News,
5/15/05
by Heidi Splete
| |
|
|
FDA Approves Once-Monthly Boniva(R) for Osteoporosis
The U.S. Food and Drug Administration (FDA) today approved once-monthly oral Boniva® (ibandronate sodium) 150 mg Tablets, the first and only once-a-month ...
From Market Wire,
3/25/05
| |
|